Sector News

Teva announces appointment of new Chief Legal Officer

November 11, 2016
Life sciences

Teva Pharmaceutical Industries Ltd. today announced the appointment of Mr. David Stark to the position of Chief Legal Officer. Stark is joining the Company’s executive leadership team and will replace Mr. Richard Egosi, who is taking a leave of absence.

“David has been an integral part of Teva’s stellar legal team since his arrival to Teva in 2002,” stated Erez Vigodman, Teva’s President and CEO. “Having most recently served as Deputy Chief Legal Officer, David led the Legal Group on a number of key achievements including the successful negotiation and close of Actavis Generics and Anda, and a series of key legal wins. He has shown the leadership capabilities needed to provide Teva with the best counsel it requires in order to deliver on its strategy, fulfill its vision and navigate any challenges we encounter along the way.”

Vigodman added, “Rich has been invaluable throughout his 21-year tenure with the company and is looked upon throughout the generic industry as an insightful and innovative thinker, due to his success in initially propelling the US generic business to its leadership position. Rich has been a key contributor to Teva’s growth, providing professional expertise, guidance and insight to both its executive management and Board, as well cultivating an exemplary legal department. We are pleased he will continue his career at Teva and look forward to his continued contribution and support.”

David Stark – Key Biographical Details
David Stark has amassed over 20 years of legal experience beginning with a series of New York law firms followed by a distinguished career at Teva. Since joining Teva in 2002, Mr. Stark served in a series of roles of increased responsibility in Teva North America and Teva Americas between 2002 and 2013, including Senior Director, Deputy General Counsel, and Vice President and General Counsel. In 2013 he was appointed Senior Vice President and General Counsel, Global Specialty Medicines, adding the position of Deputy Chief Legal Officer in 2016. Between 2014 and 2015 he also served as Acting Chief Legal Officer.

Prior to joining Teva, Mr. Stark served as an associate in the litigation departments of Haight, Gardner, Poor & Havens (1994-1997), Chadbourne & Parke (1997-1998), and Willkie Farr & Gallagher (1998-2002).

Source: Teva

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.